Table 2.
Therapeutic aspects.
| Variables | N = 194 | Percentages (%) |
|---|---|---|
| Therapeutic classes | ||
| Angiotensin-converting enzyme inhibitors | 9 | 4.6 |
| Calcium channel blocker | 18 | 9.3 |
| Central Antihypertensive Drugs | 2 | 1.0 |
| Angiotensin II Receptor Blockers | 3 | 1.5 |
| Diuretic + Angiotensin-converting enzyme inhibitors | 35 | 18.0 |
| Diuretic + Angiotensin II Receptor Blockers | 12 | 6.2 |
| Beta-blockers + Calcium channel blocker | 1 | 0.5 |
| Angiotensin-converting enzyme inhibitors + Calcium channel blocker | 59 | 30.41 |
| Angiotensin II Receptor Blockers + Calcium channel blocker | 13 | 6.7 |
| Calcium channel blocker + Diuretic | 11 | 5.7 |
| Diuretic + Beta-blockers | 2 | 1 |
| Angiotensin II Receptor Blockers + Calcium channel blocker + Diuretic | 9 | 4.6 |
| Angiotensin-converting enzyme inhibitors + Calcium channel blocker + Diuretic | 10 | 5.2 |
| Angiotensin-converting enzyme inhibitors + Calcium channel blocker + Diuretic + Beta-blockers | 2 | 1.0 |
| Treatment strategy | ||
| Monotherapy | 32 | 16.49 |
| Dual therapy | 133 | 68.55 |
| Triple therapy | 27 | 13.91 |
| Quadritherapy | 2 | 1 |
| Fixed combination | 152 | 78.35 |
| Therapeutic adherence | 73 | 37.6 |
| Normalization of BP | 49 | 25.25 |